BURLINGTON, Vt. -- Triosyn Corp., a developer of products aimed at protecting against microbial threats, announced today that tests conducted by Health Canada's National Microbiology Laboratory show that Triosyn T-1000 Series Respirators protect against Severe Acute Respiratory Syndrome (SARS). The third-party tests, which validate Triosyn's extensive testing, demonstrate that Triosyn's unique filtration technology eliminates SARS viral particles from the air passing through the facemask.
Health Canada, the Canadian federal bureau of health, conducted
independent testing on the efficacy of Triosyn's facemask filter to protect
against SARS coronavirus, the viral agent responsible for SARS. The test
involved blowing air contaminated with the SARS coronavirus through the
facemask and analyzing the airstreams that passed through the facemask for the
presence of viral particles. Tests were conducted at three different exposure
periods: 15, 60 and 120 minutes. Health Canada's test results show that no
coronavirus particles were detected in the airstreams that passed through the
Triosyn T-1000 Series Respirator during any of the three different exposure
periods.
"Health Canada's tests confirm that the T-1000 is the world's first
personal facemask that can provide protection against the potentially deadly
airborne SARS virus," said Pierre Jean Messier, CEO of Triosyn Corp. "Police forces in North America are currently using the T-1000
facemask and we are introducing it throughout the world."
SARS is a potentially deadly respiratory virus which currently has no
vaccine. More than 8,400 people in 29 countries have contracted SARS and more
than 900 people have died worldwide since the emergence of SARS in November
2002. The World Health Organization states that the virus can be transmitted
through the air, via coughing or sneezing, on tiny droplets of bodily fluids.
The Triosyn T-1000 Respirator, a disposable personal facemask manufactured
with an innovative antimicrobial technology to protect the filtration
materials from microbial deterioration, is certified by the National Institute
for Occupational Safety and Heath (NIOSH) as an N95 filtering facepiece
respirator. It is also CE certified in Europe.
Source: Triosyn Corp.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.